{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:26Z","timestamp":1786982666933,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:00:00Z","timestamp":1749945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01450-x","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T09:12:23Z","timestamp":1749978743000},"page":"2803-2816","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase\u00a0II Clinical trial"],"prefix":"10.1007","volume":"15","author":[{"given":"Lin","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congjun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,15]]},"reference":[{"issue":"10275","key":"1450_CR1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754\u201366.","journal-title":"Lancet"},{"key":"1450_CR2","doi-asserted-by":"publisher","first-page":"1308822","DOI":"10.3389\/fendo.2024.1308822","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Dong S, Ma Y, Mou Y. Burden of psoriasis in young adults worldwide from the global burden of disease study 2019. Front Endocrinol. 2024;15:1308822.","journal-title":"Front Endocrinol"},{"issue":"10","key":"1450_CR3","first-page":"965","volume":"56","author":"H Yu","year":"2023","unstructured":"Yu H, Heng G, Chen K. Disease burden and unmet medical needs in Chinese patients with moderate-to-severe psoriasis: a systematic review. Chin J Dermatol. 2023;56(10):965\u201372.","journal-title":"Chin J Dermatol"},{"issue":"28","key":"1450_CR4","doi-asserted-by":"publisher","first-page":"46381","DOI":"10.18632\/oncotarget.18453","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, Wang G, Jin H, et al. Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget. 2017;8(28):46381.","journal-title":"Oncotarget"},{"issue":"1","key":"1450_CR5","doi-asserted-by":"publisher","first-page":"2337264","DOI":"10.1080\/09546634.2024.2337264","volume":"35","author":"Y Gao","year":"2024","unstructured":"Gao Y, Li C, Tong M, Hu Y, Li Y. Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center. J Dermatol Treat. 2024;35(1):2337264.","journal-title":"J Dermatol Treat"},{"key":"1450_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113388","volume":"143","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Verduci C, Laconi E, et al. Current therapeutic overview and future perspectives regarding the treatment of psoriasis. Int Immunopharmacol. 2024;143:113388.","journal-title":"Int Immunopharmacol"},{"issue":"22","key":"1450_CR7","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1097\/CM9.0000000000001163","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai L, Zhang J-Z, Yao X, et al. Secukinumab demonstrates high efficacy and a favorable safety profile over 52\u00a0weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J. 2020;133(22):2665\u201373.","journal-title":"Chin Med J"},{"key":"1450_CR8","doi-asserted-by":"crossref","unstructured":"Blair HA. Xeligekimab: first approval. Drugs. 2024:1\u20135.","DOI":"10.1007\/s40265-024-02125-1"},{"issue":"11","key":"1450_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-039067","volume":"10","author":"W Dong","year":"2020","unstructured":"Dong W, Nie X, Wang J, et al. Randomised, double-blind, multicentre, phase\u00a0I\/II dose escalation and expansion trial of GR1501 in patients with plaque psoriasis: study protocol. BMJ Open. 2020;10(11):e039067.","journal-title":"BMJ Open"},{"key":"1450_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1\u201310.","journal-title":"Arch Dermatol Res"},{"key":"1450_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-018-0279-5","volume":"9","author":"BE Strober","year":"2019","unstructured":"Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther. 2019;9:5\u201318.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1450_CR12","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1080\/09546634.2016.1278198","volume":"28","author":"M Abrouk","year":"2017","unstructured":"Abrouk M, Nakamura M, Zhu T, Farahnik B, Koo J, Bhutani T. The impact of PASI\u00a075 and PASI\u00a090 on quality of life in moderate to severe psoriasis patients. J Dermatol Treat. 2017;28(6):488\u201391.","journal-title":"J Dermatol Treat"},{"key":"1450_CR13","doi-asserted-by":"crossref","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137\u201374.","DOI":"10.1016\/j.jaad.2010.11.055"},{"issue":"5","key":"1450_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","volume":"63","author":"AS Paller","year":"2010","unstructured":"Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1450_CR15","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1450_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1450_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/07853890.2021.1986637","volume":"53","author":"I Belinch\u00f3n Romero","year":"2021","unstructured":"Belinch\u00f3n Romero I, Dauden E, Ferr\u00e1ndiz Foraster C, Gonz\u00e1lez-Cantero \u00c1, Carrascosa Carrillo JM. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med. 2021;53(1):1727\u201336.","journal-title":"Ann Med"},{"issue":"4","key":"1450_CR18","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al. Phase\u00a03 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"4","key":"1450_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis\u2014results of two phase\u00a03 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"key":"1450_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther. 2021;11:235\u201352.","journal-title":"Dermatol Ther"},{"key":"1450_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s13555-019-0310-5","volume":"9","author":"Y-W Huang","year":"2019","unstructured":"Huang Y-W, Tsai T-F. Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: a 15-year single-center experience. Dermatol Ther. 2019;9:553\u201369.","journal-title":"Dermatol Ther"}],"updated-by":[{"DOI":"10.1007\/s13555-025-01480-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01450-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:04:49Z","timestamp":1758719089000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01450-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,15]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01450-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,15]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-025-01480-5","URL":"https:\/\/doi.org\/10.1007\/s13555-025-01480-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lin Cai, Chengxin Li, Shanshan Li, Xiaodong Zhang, Gang Wang, Jianbin Yu, Kun Huang, Hong Fang, Yangfeng Ding, Jinyan Wang, Congjun Jiang, Qianjin Lu, Juan Tao, and Jianzhong Zhang declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The ethics committees of each study center reviewed the study protocol and informed consent requirements (2020PHA072-001, GR1501-004). The study was conducted according to the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from each patient before randomization. The trial registered with the number of ChiCTR1800017956.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}